Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 14/20 | 0.46 |
| ▸ | AGTR2 | P50052 | 12/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | BRS3 | P32247 | 1/20 | 0.44 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6007173 | 0.89 | AGTR1 (0.59) | AGTR1AGTR2BRS3 | |
| SCHEMBL9739525 | 0.85 | AGTR1 (0.54) | AGTR1AGTR2MME | |
| SCHEMBL9532017 | 0.83 | AGTR1 (0.55) | AGTR1AGTR2FOLH1BRS3LTB4R | |
| SCHEMBL9528498 | 0.82 | AGTR1 (0.42) | AGTR1AGTR2FOLH1BRS3LTB4R | |
| SCHEMBL9749873 | 0.82 | FOLH1 (0.48) | AGTR1AGTR2FOLH1BRS3LTB4R | |
| SCHEMBL6005835 | 0.79 | AGTR1 (0.59) | AGTR1AGTR2BRS3 | |
| SCHEMBL6004585 | 0.78 | AGTR1 (0.72) | AGTR1AGTR2 | |
| SCHEMBL6006974 | 0.78 | AGTR1 (0.60) | AGTR1AGTR2BRS3 | |
| SCHEMBL6008006 | 0.78 | AGTR1 (0.60) | AGTR1AGTR2BRS3 | |
| SCHEMBL6007460 | 0.77 | AGTR1 (0.63) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0527851-A1 | 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1993-02-24 | — | — | EP | disclosed |
| WO-1991017148-A1 | 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1991-11-14 | — | — | WO | disclosed |